



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 19/06, A61K 31/70		A1	(11) International Publication Number: WO 95/21183
			(43) International Publication Date: 10 August 1995 (10.08.95)
(21) International Application Number: PCT/CA95/00048		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TO), ARIPO patent (KE, MW, SD, SZ).	
(22) International Filing Date: 1 February 1995 (01.02.95)			
(30) Priority Data: 08/191,192 2 February 1994 (02.02.94) US			
(71) Applicant: ACID (CANADA) INC. [CA/CA]; 34 Spalding Drive, Brantford, Ontario N3T 6B8 (CA).		Published With international search report.	
(72) Inventors: RADATUS, Bruno, Konrad; Apartment 307, 24 Hellen Avenue, Brantford, Ontario N3T 5Y8 (CA). KARIMIAN, Khashayar; 15 Irongate Place, Brantford, Ontario N3R 5V6 (CA). DALJEET, Anand; 2036 Wincanton Crescent, Mississauga, Ontario L5M 3E2 (CA). MURTHY, Keshava; 43 Hobart Crescent, Brantford, Ontario N3P 1V5 (CA).			
(74) Agents: NASSIF, Omar, A. et al.; McCarthy Tétrault, Suite 4700, Toronto Dominion Bank Tower, Toronto-Dominion Centre, Toronto, Ontario M5K 1E6 (CA).			
(54) Title: HALOGENATED DERIVATIVES OF 2,3'-O-CYCLOCYTIDINE COMPOUNDS AND PROCESS FOR PRODUCTION THEREOF			
(57) Abstract			
<p>In one of its aspects, the present invention provides novel compounds of formula (I) wherein: X is a halide; Y is selected from the group consisting essentially of halide, sulfate, acetate, tosyl, mesyl, benzoate and phosphate; R¹ is selected from the group consisting essentially of hydrogen, a substituted or unsubstituted C₁-C₁₀ alkyl group and a substituted or unsubstituted C₆-C₁₀ aryl group; and R² is selected from the group consisting essentially of hydrogen, trityl, acetyl, benzyl, benzoyl, dimethoxy trityl, tosyl, mesyl and an acyl radical of an organic carboxylic acid (a) in which R is selected from the group consisting essentially of a substituted or unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₆-C₁₀ aryl group, a substituted or unsubstituted C₄-C₁₀ cycloalkyl group, a substituted or unsubstituted C₇-C₁₂ aralkyl group and a substituted or unsubstituted C₇-C₂₀ cage-type hydrocarbon group. A process for produce compounds of formula (I) is described. The compounds of formula (I) are useful as antineoplastic and antiviral agents.</p>			
<div style="display: flex; align-items: center; justify-content: center;"> <div style="text-align: center;"> <p>(I)</p> </div> <div style="margin-left: 20px;"> <p>(a)</p> </div> </div>			

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NR	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
DJ	Dominica	IT	Italy	PL	Poland
RR	Dominican Republic	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

HALOGENATED DERIVATIVES OF 2,3'-O-CYCLOCYTIDINE
COMPOUNDS AND PROCESS FOR PRODUCTION THEREOF

TECHNICAL FIELD

5 The present invention relates to novel halogenated derivatives of 2,3'-O-cyclocytidine compounds and to a process for production thereof.

BACKGROUND ART


10 Mizuno et al. (Tet. Lett., 4579-4584 (1965)), the contents of which are incorporated herein by reference, teach the production of 2,3'-O-cyclocytidine via a six step process which includes the production of 3'-O-mesylcytidine via a four step process from N⁴-acetylcytidine. This corresponds to a five step process, overall, if cytidine is used as the starting material. Thus, it is not surprising that the overall yield of 3'-O-mesylcytidine produced in this manner is less than 10% (even this low
15 yield assumes theoretical yields for two of the five steps where yield was unreported). As taught in Mizuno et al. (Tet. Lett., 4579-4584 (1965)), 2,3'-O-cyclocytidine is produced from 3'-O-mesylcytidine as a crystalline free-base. Specifically, the last step in the process comprises reacting 3'-
20 O-mesylcytidine with an excess of sodium t-butoxide to produce 2,3'-O-cyclocytidine. Unfortunately, the first step in the process involves conversion of N⁴-acetylcytidine (NOTE: this was obtained from cytidine in only a 65% yield) to 2',5'-di-O-trityl-N⁴-acetylcytidine in only a 20% yield. Accordingly, the process of Mizuno et al. is deficient in that it
25 requires an onerous number of steps to produce 2,3'-O-cyclocytidine and, when produced, 2,3'-O-cyclocytidine is obtained in a relatively low yield of less than 8.5% (even this low yield assumes theoretical yields for two of the six steps where yield was unreported).

30 Further, Doerr et al. (J. Org. Chem., 32, 1462-1471 (1967)), the contents of which are incorporated herein by reference, found it


-2-

surprising that Mizuno et al. reported isolating 2,3'-*O*-cyclocytidine in neutral form.

These problems of low yields of 2,3'-*O*-cyclocytidine has been addressed by Karimian et al. in International patent application S.N. 5 PCT/CA91/00078 (published September 19, 1991 as WO 91/13901), the contents of which are incorporated herein by reference. Specifically, Karimian et al. teach that the hydrochloride salt of 2,3'-*O*-cyclocytidine, Formula II,



may be produced in relatively high yields by a reaction comprising the step of intramolecular rearrangement of a compound having the formula



wherein Ts is a tosyl group, followed by reaction with hydrogen chloride, 30 to produce the compound of Formula II.

-3-

As is known in the art, 2,3'-*O*-cyclocytidine (including its salts, analogues and derivatives) has utility as an antineoplastic and an antiviral agent.


There is an ongoing need to develop compounds related to 2,3'-*O*-cyclocytidine which have similar or enhanced activity as antineoplastic and antiviral agents.

DISCLOSURE OF THE INVENTION

It is an object of the present invention to provide novel halogenated 2,3'-*O*-cyclocytidine compounds.

It is another object of the present invention to provide a process for producing halogenated 2,3'-*O*-cyclocytidine compounds.

Accordingly, in one of its aspects, the present invention provides a compound of Formula I:



wherein:

X is a halide;

Y is selected from the group consisting essentially of halide, sulfate, acetate, tosyl, mesyl, benzoate and phosphate;

R¹ is selected from the group consisting essentially of hydrogen, a substituted or unsubstituted C₁-C₁₀ alkyl group and a substituted or unsubstituted C₆-C₁₀ aryl group; and

-4-

R^2 is selected from the group consisting essentially of hydrogen, trityl, acetyl, benzyl, benzoyl, dimethoxy trityl, tosyl, mesyl and an acyl radical of an organic carboxylic acid


5



in which R is selected from the group consisting essentially of a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_6 - C_{10} aryl group, a substituted or unsubstituted C_4 - C_{10} cycloalkyl group, a substituted or unsubstituted C_7 - C_{12} aralkyl group and a substituted or unsubstituted C_7 - C_{20} cage-type hydrocarbon group.

In another of its aspects, the present invention provides a process for producing a compound of Formula I:

20



25 wherein:

X is a halide;

Y is selected from the group consisting essentially of halide, sulfate and acetate;


-5-

R¹ is selected from the group consisting essentially of hydrogen, a substituted or unsubstituted C₁-C₁₀ alkyl group and a substituted or unsubstituted C₆-C₁₀ aryl group; and

R² is selected from the group consisting essentially of hydrogen, trityl, acetyl, benzyl, benzoyl, dimethoxy trityl, tosyl, mesyl and an acyl radical of an organic carboxylic acid



in which R is selected from the group consisting essentially of a substituted or unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₆-C₁₀ aryl group, a substituted or unsubstituted C₄-C₁₀ cycloalkyl group, a substituted or unsubstituted C₇-C₁₂ aralkyl group and a substituted or unsubstituted C₇-C₂₀ cage-type hydrocarbon group, the process comprising the step of reacting a compound of Formula II:



with a halogenating compound comprising X.

30

-6-

BRIEF DESCRIPTION OF THE DRAWING

Embodiments of the invention will be described with reference to the attached Figure which is a graphical illustration of % Radioactivity vs. Concentration (μM) for various compounds.

5


BEST MODE FOR CARRYING OUT THE INVENTION

The present inventors have discovered that halogenated derivatives of 2,3'-O-cyclocytidine compounds (i.e. the compounds of Formula I) have a surprising and unexpected superior activity compared to their non-halogenated analogues (i.e. the compounds of Formula II).

10

In the compounds of Formula I

15



20

X is a halide and Y is selected from the group consisting essentially of halide, sulfate and acetate. Thus, when both X and Y are halide, they may be independently selected from the group comprising chloride, bromide, fluoride and iodide. Preferably, X is chloride or bromide, more preferably bromide. Preferably, Y is chloride.

25

The group R^1 is selected from hydrogen, a substituted or unsubstituted C_1 - C_{10} alkyl group and a substituted or unsubstituted C_6 - C_{10} aryl group. Preferably, R^1 is selected from the group consisting essentially of hydrogen, methyl, ethyl, propyl, isopropyl, *n*-butyl and *t*-butyl, benzyl, phenyl. Most preferably, R^1 is hydrogen.

30

-7-

The group R^2 is selected from the group consisting essentially of hydrogen, trityl, aceryl, benzyl, benzoyl, dimethoxy trityl, tosyl, mesyl and an acyl radical of an organic carboxylic acid

5




in which R is selected from the group consisting essentially of a substituted or unsubstituted C_1 - C_{20} alkyl group, a substituted or unsubstituted C_6 - C_{10} aryl group, a substituted or unsubstituted C_4 - C_{10} cycloalkyl group, a substituted or unsubstituted C_7 - C_{12} aralkyl group and a substituted or unsubstituted C_7 - C_{20} cage-type hydrocarbon group. Preferably, the C_1 - C_{20} alkyl group is selected from the group consisting essentially of methyl, ethyl, propyl, isopropyl, *n*-butyl and *t*-butyl. Preferably, the C_6 - C_{10} aryl group is selected from the group benzyl, phenyl, tolyl and xylyl. Non-limiting examples of suitable cage-type hydrocarbon group may be found in United States patent 4,118,484 (Wechter et al.), the contents of which are incorporated herein by reference. The preferred choice for R^2 is hydrogen.

The term "substituted" as used in reference to various hydrocarbons of R^1 and R^2 , is meant to encompass such groups substituted by one or more members selected from the group comprising halide, hydroxyl, carboxyl (C_1 - C_{10}), nitro, alkoxy (C_1 - C_{10}) and mercapto substituents.

The compounds of Formula I may be produced by reacting a compound of Formula II:

30

-8-



10 with a halogenating compound comprising X. As used throughout this specification, the term "halogenating compound" means a compound or compounds which, when reacted with a compound of Formula II will result in transfer of a halide (X) to form a compound of Formula I. The choice of halogenating compound is within the purview of a person skilled in the art and will depend on considerations such as the choice of
 15 halide (X), the conditions under which the reaction will be conducted and the like - see, for example, Volume 24 of STUDIES IN ORGANIC CHEMISTRY, entitled "The Organic Chemistry of Nucleic Acids" by Yoshihisa Mizuno, pgs. 124-133, the contents of which are incorporated
 20 herein by reference.

When X and Y are chloride, and R¹ and R² are hydrogen, the compound of Formula I is 5-chloro-2,3'-O-cyclocytidine hydrochloride. In this embodiment of the invention, it is preferred to prepare the compound of Formula I by reacting 2,3'-O-cyclocytidine hydrochloride
 25 with a halogenating compound such as N-chlorosuccinimide in an acidic medium. The reaction can be carried out in an aqueous or non-aqueous acidic medium, preferably a non-aqueous acidic medium. Non-limiting examples of suitable acidic media include acetic acid, trifluoroacetic acid and mixtures thereof. The preferred acidic medium is trifluoroacetic
 30 acid. Also, protic solvents such as alcohols can be used as co-solvents.

An alternative approach is to react 2,3'-*O*-cyclocytidine hydrochloride in an acidic medium with chlorine dissolved in a suitable solvent (e.g. carbon tetrachloride). The crude product may then be worked up and recrystallized using conventional techniques.

- 5 When X is bromide, Y is chloride and R is hydrogen, the compound of Formula I is 5-bromo-2,3'-*O*-cyclocytidine hydrochloride. In this embodiment of the invention, it is preferred to prepare the compound of Formula I by reacting 2,3'-*O*-cyclocytidine hydrochloride with a halogenating compound such as N-bromosuccinimide or 1,3-
10 dibromo-5,5-dimethyl hydantoin in an acidic medium. The reaction can be carried out in an aqueous or non-aqueous acidic medium, preferably a non-aqueous acidic medium. Non-limiting examples of suitable acidic media include acetic acid, trifluoroacetic acid and mixtures thereof. The preferred acidic medium is trifluoroacetic acid. Also, protic solvents
15 such as alcohols can be used as co-solvents. An alternative approach is to react 2,3'-*O*-cyclocytidine hydrochloride in an acidic medium with bromine dissolved in a suitable solvent. The crude product may then be worked up and recrystallized using conventional techniques. The solvent is preferably a mixture of water and protic or non-protic polar solvents.
20 Non-limiting examples of such a solvent include methanol, ethanol, isopropanol, pyridine, dimethyl formamide, acetonitrile, acetone and mixtures thereof.

- When X is fluoride, Y is chloride, and R¹ and R² are hydrogen, the compound of Formula I is 5-fluoro-2,3'-*O*-cyclocytidine
25 hydrochloride. In this embodiment of the invention, it is preferred to prepare the compound of Formula I by reacting 2,3'-*O*-cyclocytidine hydrochloride with a halogenating compound such as trifluoromethyl hypofluorite, cesium fluoroxysulfate, fluorine, N-fluoro-*O*-benzene-disulfonimide and mixtures thereof in an inert solvent. The crude

-10-

product may then be worked up and recrystallized using conventional techniques.

When X is iodide, Y is chloride, and R¹ and R² are hydrogen, the compound of Formula I is 5-iodo-2,3'-O-cyclocytidine hydrochloride. In this embodiment of the invention, it is preferred to prepare the compound of Formula I by reacting 2,3'-O-cyclocytidine hydrochloride with a halogenating compound such as N-iodosuccinimide or iodine in an acidic medium. Non-limiting examples of suitable acidic medium include acetic acid, trifluoroacetic acid and mixtures thereof. The preferred aqueous acidic medium is trifluoroacetic acid. The crude product may then be worked up and recrystallized using conventional techniques.

Preferably, Y in Formulae I and II is chloride. It will be appreciated by those of skill in the art that Y in Formula II may be ion exchanged prior to reaction with the halogenating compound comprising X. Alternatively, it will be appreciated by those of skill in the art that Y in Formula I may be ion exchanged after the production thereof.

The compounds of Formula I have utility as antineoplastic and antiviral agents. Accordingly, the novel compounds may be formulated into pharmaceutical compositions for this purpose in a conventional manner within the purview of a person skilled in the art. Thus, the pharmaceutical compositions comprising at least one of the compounds of Formula I may be adapted for administration by accepted methods of administration including oral and parenteral means. Such oral compositions may take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like.

The pharmaceutical composition will typically include a pharmaceutically acceptable excipient normally employed in the formation of pharmaceutical compositions intended for administration by the known routes of administration of pharmaceuticals. For example, for compositions intended for oral administration, suitable pharmaceutical

-11-

excipients include the non-toxic pharmaceutically acceptable carriers such as starch, glucose, lactose, dextrose, sucrose, mannitol, sorbitol, gelatin, malt, rice, flour, chalk, silica gel, magnesium carbonate, magnesium stearate, sodium stearate, glyceryl, monostearate, sodium chloride, talc, dried skim milk, glycerol, propylene glycol, water, ethanol and the like. Mixtures of one or more of such carriers may also be used.

Aspects of the invention will be described with reference to the following Examples, which should not be considered to limit the scope of the invention.

10

Example 1 - Production of 5-Chloro-2,3'-O-Cyclocytidine Hydrochloride

2,3'-O-cyclocytidine hydrochloride (7.85 g; 0.03 mol) was dissolved in trifluoroacetic acid (40 mL), and thereafter, N-chlorosuccinimide (4.41 g; 0.033 mol) was added to the solution, with stirring. The reaction mixture was maintained with stirring at ambient conditions.

Periodically, an aliquot of the reaction mixture was removed and dispensed into an NMR tube and an ¹H NMR spectrum was obtained using a 60 MHz NMR spectrometer. The reaction was judged complete after 70 minutes when the H-5 doublet of 2,3'-O-cyclocytidine hydrochloride substantially disappeared and the H-6 singlet of 5-chloro-2,3'-O-cyclocytidine hydrochloride appeared.

The solution was then evaporated under reduced pressure to produce a thick syrup. In a successive manner, ethanol (50 mL), water (30 mL) and ethanol (30 mL) were added to the syrup and thereafter evaporated under reduced pressure to yield 22 g of thick syrup.

Hydrochloric acid (32%; 6 g; 0.053 mol) and ethanol (30 mL) were added to the thick syrup and heated slightly to dissolve the syrup. Upon cooling, a mass of crystals was formed which were filtered and washed with ethanol. The crystals (5 g) had a melting point of 183°-

-12-

185°C and were determined to be impure by virtue of the fact that the NMR spectrum indicated a trace amount of the starting material 2,3'-*O*-cyclocytidine hydrochloride.

The crystals were recrystallized by: (i) dissolving in a mixture of water (4 mL) and ethanol (25 mL) with slight heating; (ii) evaporating the solution to a small volume under reduced pressure; and (iii) adding another portion of ethanol (25 mL) to induce crystallization. The crystals were gravity filtered and washed with ethanol to provide a yield of 4.0 g (45% of theoretical; 0.0135 mol) of pure 5-chloro-2,3'-*O*-cyclocytidine hydrochloride, which had a melting point of 190°-192°C.

The pure product was subject to elemental analysis assuming a molecular formula of $C_9H_{11}Cl_2N_3O_4$. The results of this elemental analysis are provided in Table 1.

Table 1

Element	Calculated	Found
Carbon	36.51	36.51
Hydrogen	3.74	3.62
Nitrogen	14.19	14.09
Chlorine	23.95	23.76

Using a 500 MHz NMR spectrometer, an 1H NMR spectrum of the pure product in DMSO-d₆ was obtained. Data on peak shifts, number of peaks and coupling constants in the 1H NMR spectrum are reported in Table 2.

Using a 125 MHz NMR spectrometer, a ^{13}C NMR spectrum of the pure product in DMSO-d₆ was also obtained. Data on peak shifts in the

-13-

¹³C NMR spectrum together with the assignment of carbons are reported in Table 3.

As will be apparent from Tables 2 and 3, the data presented confirm the structure of the product to be consistent with 5-chloro-2,3'-

5 *O*-cyclocytidine hydrochloride.

Table 2

¹ H NMR Spectrum (DMSO-d ₆ , 500 MHz)	
Shift (δ)	Assignment
3.64, ABm	2H; J _{4'5'} ₁ = J _{4'5'} ₂ = 5.5 Hz: H-5' ₁ and H-5' ₂
4.49, td	1H; J _{3'4'} = 2.5 Hz: H-4'
4.88, d	1H; J _{2'OH} = 3.8 Hz: H-2'
5.14, t	1H; J _{5'1OH} = J _{5'2OH} = 5.1 Hz, exchangeable: C5'-OH
5.21, bs	1H: H-3'
5.96, s	1H: H-1'
6.91, d	1H; exchangeable: C2'-OH
8.86, s	1H: H-6
8.09 and 9.76, 2 x bs	2H; exchangeable: NH ₂ ⁺

20 Example 2 - Production of 5-Bromo-2,3'-*O*-Cyclocytidine Hydrochloride
(Method Δ)

2,3'-*O*-cyclocytidine hydrochloride (78.5 g; 0.3 mol) was suspended in a mixture of acetic acid (300 mL) and trifluoroacetic acid

-14-

(250 mL). After 30 minutes of stirring the mixture, substantially all of the solid had dissolved.

Table 3

5

¹³ C NMR Spectrum (DMSO-d ₆ , 125 MHz)	
Shift (δ)	Assignment
58.2	C-5'
69.1	C-3'
81.5	C-2'
84.3	C-4'
90.8	C-1'
107.0	C-5
142.6	C-6
153.5	C-2
162.2	C-4

10

15

Bromine (57.88 g; 0.362 mol) dissolved in carbon tetrachloride (200 mL) was then added dropwise to the mixture over a period of 5½ hours. When approximately ¼ of the bromine had been added, a precipitate had formed. The reaction was monitored by taking aliquots of the reaction mixture and running NMR spectra on same as described in Example 1.

20

After 24 hours, most of the precipitate had dissolved and the reaction was judged to be complete using the NMR technique described above in Example 1.

25

-15-

Water (300 mL) was added and resulted in the production of a two-phase reaction mixture. The two phases were separated and the top, aqueous phase was extracted with carbon tetrachloride (2 x 75 mL). The lower, organic phase was combined with the carbon tetrachloride extracts and extracted once with water (200 mL). The aqueous phases were
5 combined and evaporated under reduced pressure to produce a thick syrup.

A mixture of ethanol (250 mL) and hydrochloric acid (32%; 100 mL) was added to the syrup and evaporated under reduced pressure.
10 Ethanol (250 mL) was then added and the entire mixture was evaporated under reduced pressure to produce again a thick syrup.

Ethanol (150 mL) containing acetyl chloride (72 mL) was added to the syrup resulting in formation of a gum. The mixture was then heated to 55°C and hydrochloric acid (32%; 25 mL) was added resulting
15 in dissolution of the gum. Crystallization seeds were then added to the mixture. After 15 minutes of cooling, an oil appeared to form. More hydrochloric acid (32%; 55 mL) was added and the mixture was heated. Upon cooling, crystallization seeds were added to the mixture resulting in formation of crystals.

20 After a period of 4 hours, the crystals were filtered and washed with ethanol (3 x 50 mL). The washed crystals were allowed to air dry to yield 27.1 g (26.6% of theoretical; 0.0798 mol) of a first batch of crystalline product.

The mother liquor from the reaction and the wash liquids were
25 returned to the crystallization flask (which also contained crystalline material) and stirring thereof was resumed. After 14 hours, the crystals were filtered and washed with ethanol to yield 26.16 g (25.6% of theoretical; 0.0768 mol) of a second batch of crystalline product. Concentration of the mother liquor yielded 1.6 g of a third batch of
30 crystalline product.

-16-

The three batches of crystalline product were combined and dissolved in a mixture of water (90 mL) and hydrochloric acid (32%; 30 mL). The resulting mixture was evaporated under reduced pressure to produce a thin syrup. Ethanol (220 mL) and crystallization seeds were then added resulting in the production of crystals. After 20 hours, the crystals were filtered, washed with ethanol (2 x 50 mL) and air dried to provide a yield of 42.3 g (41.4% of theoretical; 0.124 mol) of pure 5-bromo-2,3'-*O*-cyclocytidine hydrochloride, which had a melting point of 179°-182°C.

The pure product was subjected to elemental analysis assuming a molecular formula of $C_9H_{11}BrClN_3O_4$. The results of this elemental analysis are provided in Table 4. These results indicated that the cyclocytidine was present partially as the hydrobromide salt since the result yielded an empirical formula of $C_9H_{11}Br_{1.1}Cl_{0.9}N_3O_{3.9}$.

Table 4

Element	Calculated	Found
Carbon	31.74	31.62
Hydrogen	3.26	3.24
Nitrogen	12.09	12.09
Bromine	23.46	25.42
Chlorine	10.41	9.17

1H and ^{13}C NMR spectra of the product were obtained and the data therefrom are reported in Tables 5 and 6, respectively. As will be apparent from Tables 5 and 6, the data presented confirm the structure of the product to be consistent with 5-bromo-2,3'-*O*-cyclocytidine

-17-

hydrochloride. In this regard, it is noted that while the ^1H spectra for 5-chloro-2,3'-O-cyclocytidine hydrochloride and 5-bromo-2,3'-O-cyclocytidine hydrochloride are similar, the corresponding ^{13}C spectra distinguish the compounds from one another.

5

Table 5

^1H NMR Spectrum (DMSO-d-6, 500 MHz)	
Shift (δ)	Assignment
3.64, ABm	2H; $J_{4'5'_1} = J_{4'5'_2} = 5.5$ Hz: H-5' ₁ and H-5' ₂
4.49, td	1H; $J_{3'4'} = 2.5$ Hz: H-4'
4.87, d	1H; $J_{2'\text{OH}} = 3.9$ Hz: H-2'
5.13, m	1H; exchangeable: C5'-OH
5.21, bs	1H: H-3'
5.94, s	1H: H-1'
6.90, d	1H; exchangeable: C2'-OH
8.87, s	1H: H-6
8.85 and 9.73, 2 x bs	2H; exchangeable: NH_2^+

10

15

Example 3 - Production of 5-Bromo-2,3'-O-Cyclocytidine Hydrochloride

20

(Method B)

2,3'-O-cyclocytidine hydrochloride (15.7 g; 0.06 mol) was dissolved in trifluoroacetic acid (80 mL), and thereafter, N-bromosuccinimide (11.87 g; 0.066 mol) was added to the solution, with

stirring. The reaction mixture was maintained with stirring at ambient conditions.

Table 6

5

¹³ C NMR Spectrum (DMSO-d-6, 125 MHz)	
Shift (δ)	Assignment
58.2	C-5'
69.1	C-3'
81.4	C-2'
84.2	C-4'
90.7	C-1'
94.8	C-5
145.1	C-6
153.8	C-2
163.0	C-4

10

15

The reaction was monitored using the NMR technique described above in Example 1 and judged to be complete after 75 minutes.

The reaction mixture was then evaporated under reduced pressure to produce a thick syrup. In a successive manner, ethanol (2 x 100 mL), water (50 mL) and ethanol (100 mL) were added to the syrup and thereafter evaporated under reduced pressure to yield again thick syrup.

Hydrochloric acid (32%; 12 g; 0.106 mol) and ethanol (60 mL) were added to the thick syrup and heated slightly to dissolve the syrup.

Upon cooling, a mass of crystals was formed which was filtered and washed with ethanol to yield 18.38 g of product.

The crystals were recrystallized by: (i) dissolving in a mixture of water (20 mL), hydrochloric acid (32%; 10 g) and ethanol (30 mL) with slight heating; (ii) evaporating the solution under reduced pressure to produce a thin syrup ; and (iii) adding a portion of hot ethanol (50 mL) to induce spontaneous crystallization. The crystals were gravity filtered and washed with ethanol to provide a yield of 17.06 g (75.9% of theoretical; 0.050 mol) of pure 5-bromo-2,3'-O-cyclocytidine hydrochloride, which had a melting point of 185°-186°C.

The pure product was subjected to elemental analysis assuming a molecular formula of $C_9H_{11}BrClN_3O_4$. The results of this elemental analysis are provided in Table 7.

Table 7

Element	Calculated	Found
Carbon	31.74	31.98
Hydrogen	3.26	3.27
Nitrogen	12.09	12.27
Bromine	23.46	23.53
Chlorine	10.41	10.20

Example 4 - Production of 5-Iodo-2,3'-O-Cyclocytidine Hydrochloride

2,3'-O-cyclocytidine hydrochloride (7.85 g; 0.03 mol) was dissolved in trifluoroacetic acid (40 mL), and thereafter, 95% N-iodosuccinimide (7.82 g; 0.033 mol) suspended in trifluoroacetic acid (40 mL) was added to the solution, with stirring. The reaction mixture was

-20-

maintained with stirring at ambient conditions and the reaction was monitored using the NMR technique described above in Example 1.

After a period of 5 hours, an oil had formed on the surface of the reaction mixture. The reaction mixture was decanted to isolate the oil
5 which was then dissolved in acetic acid (80 mL) with warming and the two acid solutions were combined. An NMR spectrum of an aliquot of the reaction mixture indicated that the reaction was about 30% complete.

After a further period of 22 hours, more 95% N-iodosuccinimide (5.2 g; 0.02 mol) was added to the mixture. After a still further period
10 of 14 hours, more 95% N-iodosuccinimide (5.2 g; 0.02 mol) was added to the mixture. Using the NMR technique described above in Example 1, the reaction was judged complete after a further period of 4 days, notwithstanding the fact that some starting material (< 10%) was present.

The reaction mixture was then evaporated to produce a thick gum
15 (32 g). Ethanol (2 x 25 mL) and hydrochloric acid (32%; 2 x 8 g) were added and evaporated to yield a washed gum (27 g). The washed gum was dissolved in hydrochloric acid (32%; 6 g) and ethanol (30 mL), and thereafter preabsorbed on silica (40 g) and applied to a silica column (50 g). The column was initially eluted with ethyl acetate (1400 mL), which
20 was discarded, and thereafter eluted with ethanol (800 mL). The ethanol eluate was evaporated to yield a gum.

The gum was dissolved in a mixture of hydrochloric acid (32%; 5.5 g) and ethanol (5 mL) with warming. Ethanol (25 mL) was added to the solution, heated to about 70°C and an amount of water (2.6 mL)
25 sufficient to clarify the solution was added.

The solution was cooled, crystallization seeds were added thereto and left stirring overnight to induce crystallization. The resulting crystals were gravity filtered and washed with ethanol (2 x 20 mL) to yield 4.2 g (36.1% of theoretical; 0.011 mol) of pure 5-iodo-2,3'-O-cyclocytidine
30 hydrochloride, which had a melting point of 121.5°-124°C.

-21-

¹H and ¹³C NMR spectra of the product were obtained and the data therefrom are reported in Tables 8 and 9, respectively. As will be apparent from Tables 8 and 9, the data presented confirm the structure of the product to be consistent with 5-iodo-2,3'-O-cyclocytidine hydrochloride.

Table 8

¹ H NMR Spectrum (DMSO-d ₆ , 500 MHz)	
Shift (δ)	Assignment
3.62, ABm	2H; J _{4'5'} ₁ = J _{4'5'} ₂ = 5.5 Hz: H-5' ₁ and H-5' ₂
4.47, td	1H; J _{3'4'} = 2.5 Hz: H-4'
4.85, s	1H: H-2'
5.11, m	1H: C5'-OH
5.17, bs	1H: H-3'
5.90, s	1H: H-1'
6.53, bs	1H: C2'-OH
8.73, s	1H: H-6
8.43 and 9.62, 2 x bs	2H; exchangeable: NH ₂ ⁺

Example 5 - *In Vitro* Comparison Between 2,3'-O-Cyclocytidine Hydrochloride and 5-Bromo-2,3'-O-Cyclocytidine Hydrochloride

In this Example, there is described an *in vitro* comparison between 2,3'-O-cyclocytidine hydrochloride, 5-bromo-2,3'-O-cyclocytidine

-22-

hydrochloride, and 5-iodo-2,3'-*O*-cyclocytidine hydrochloride. The specific *in vitro* test involved assessing the toxicity of the compounds in a particular cell line by conducting [methyl-³H]thymidine uptake experiments.

5

Table 9

¹³ C NMR Spectrum (DMSO-d-6, 125 MHz)	
Shift (δ)	Assignment
58.3	C-5'
68.8	C-5
69.0	C-3'
81.3	C-2'
84.2	C-4'
90.5	C-1'
150.0	C-6
154.2	C-2
165.3	C-4

10

15

The particular cell line used in the Example was human alveolar
tumour cell line A549 (hereinafter referred to as A549) obtained from
The American Type Culture Collection (ATCC) as CCL 185 (lung
carcinoma, human).

Cultures were inoculated at 1 x 10⁵ cells/60 mm dish, incubated
for four days in the presence of various concentrations (see Figure) of
2,3'-*O*-cyclocytidine hydrochloride (○), 5-bromo-2,3'-*O*-cyclocytidine

25

-23-

hydrochloride (•) and 5-iodo-2,3'-O-cyclocytidine hydrochloride (■). Thereafter, the cells were incubated with a medium supplemented with [methyl-³H]thymidine (82 Ci/mmol; 5 µCi/ml) for four hours and lysed, and the amount of radioactivity incorporated into genomic DNA was measured. The IC₅₀ values (drug concentrations producing 50% cytotoxicity) for each compound illustrated in the Figure are reported in Table 10. As will be apparent from Table 10 and the Figure, at relatively low concentrations, 5-bromo-2,3'-O-cyclocytidine hydrochloride and 5-iodo-2,3'-O-cyclocytidine hydrochloride exhibit a significantly superior cytotoxic effect on A549 cells when compared to 2,3'-O-cyclocytidine hydrochloride.

Example 6 - In Vivo Comparison Between 2,3'-O-Cyclocytidine Hydrochloride, 5-Bromo-2,3'-O-cyclocytidine Hydrochloride And Other Compounds

In vivo studies were conducted comparing the effectiveness of 5-bromo-2,3'-O-cyclocytidine hydrochloride (5-Br-cycloC) with one or more of 2,3'-O-cyclocytidine hydrochloride (cycloC), 1-β-D-arabinofuranosylcytosine (Ara-C), Adriamycin (ADR) and Dacarbazine (DTIC).

TABLE 10

Compound	IC ₅₀ (µM)
2,3'-O-Cyclocytidine hydrochloride	50
5-Bromo-2,3'-O-cyclocytidine hydrochloride	40
5-Iodo-2,3'-O-cyclocytidine hydrochloride	10

More specifically, the antitumor activity of these compounds were evaluated in two human tumor cell lines engrafted in severe combined

immunodeficient (SCID) mice. The particular cell lines used in this Example were A549 (described above in Example 5) and melanoma A375 cells obtained from The American Type Culture Collection (ATCC) (hereinafter referred to as A375). Both cell lines were
5 inoculated s.c. into SCID mice and grew progressively as tumor nodules.

The results of the *in vivo* study done using A375 are reported in Table 11, while the those using A549 are reported in Table 12.

With reference to Table 11, the results support the conclusion that, in treatment of A375, 5-bromo-2,3'-O-cyclocytidine hydrochloride was
10 as effective in effecting tumor growth delay as 1-β-D-arabinofuranosylcytosine and dacarbazine, and much more effective than 2,3'-O-cyclocytidine hydrochloride. However, unlike therapy with 1-β-D-arabinofuranosylcytosine and dacarbazine, therapy with 5-bromo-2,3'-O-cyclocytidine hydrochloride resulted in no weight loss (or in two
15 instances an actual weight gain) during therapy.

With reference to Table 12, the results support the conclusion that 5-bromo-2,3'-O-cyclocytidine hydrochloride administered at 250 mg/kg i.p. daily x 7 (MTD indentified in non-tumor bearing SCID mice) significantly decreased tumor growth over a 20 day period with a growth
20 delay of 10 days. In comparison, growth delay observed with 1-β-D-arabinofuranosylcytosine (60 mg/kg i.p. daily x 7) and adriamycin (7 mg/kg i.p. x 1) was 7 and 5 days, respectively. Also significant is the fact that therapy with 5-bromo-2,3'-O-cyclocytidine hydrochloride resulted in no weight loss (or an actual weight in one stance) and a
25 survival rate of 100%. In comparision, therapy with 1-β-D-arabinofuranosylcytosine and adriamycin resulted in weight loss and a survival rate of 33.3% or less.

Table II

Experiment	Compound	Dose and Schedule	N (mice per group)	Growth Delay ¹ (Days)	Tumor Weight ² (% Inhibition)	Weight Loss ³ (% Decrease)	Survival Rate (%)
1	5-Br-cycloC	200 mg/kg i.p. daily x 7	6	10	25	0	6/6 (100)
	cycloC	1000 mg/kg i.p. daily x 7	6	2	+6	0	6/6 (100)
	Ara-C	60 mg/kg i.p. daily x 7	6	10	45	25	6/6 (100)
2	5-Br-cycloC	250 mg/kg i.p. daily x 7	6	10	43	0	5/6 (83.3)
	5-Br-cycloC	300 mg/kg i.p. x 1	6	11	45	0	2/6 (33.3)
	Ara-C	60 mg/kg i.p. daily x 7	6	11	39	25	6/6 (100)
3	5-Br-cycloC	250 mg/kg i.p. daily x 7	6	9	38	0	5/6 (83.3)
	5-Br-cycloC	250 mg/kg i.p. every other day x 7	6	12	43	+5	3/6 ⁴ (50)
	DTIC	120 mg/kg i.p. every other day x 7	6	12	53	20	6/6 (100)
4	5-Br-cycloC	250 mg/kg i.p. every other day x 7	6	11	48	+5	6/6 (100)
	DTIC	120 mg/kg i.p. every other day x 7	6	13	59	21	5/6 (83.3)

¹calculated from tumor volume curve²tumor weight at day 20³on the most significant day compared to phosphate buffered saline group⁴cage flood incident resulting in fatality

Table 12

Experiment	Compound	Dose and Schedule	N (mice per group)	Growth Delay ¹ (Days)	Tumor Weight ² (% Inhibition)	Weight Loss ³ (% Decrease)	Survival Rate (%)
1	5-Br-cycloC	250 mg/kg i.p. daily x 7	6	10	43	0	6/6 (100)
	5-Br-cycloC	250 mg/kg i.p. every other day x 7	6	6	12	+5	6/6 (100)
	ADR	7 mg/kg i.p. x 1	6	5	6	16	1/6 (16.7)
	Ara-C	60 mg/kg i.p. daily x 7	6	7	38	12	2/6 (33.3)
2	5-Br-cycloC	250 mg/kg i.p. daily x 7	6	14	48	0	6/6 (100)
	ADR	5 mg/kg i.p. x 1	6	6	24	32	1/6 (16.7)
	Ara-C	60 mg/kg i.p. daily x 7	6	11	47	32	2/6 (33.3)

¹calculated from tumor volume curve²tumor weight at day 20³on the most significant day compared to phosphate buffered saline group


-27-

What is claimed is:

1. A compound of Formula I:

5

10



wherein:

X is a halide;

15

Y is selected from the group consisting essentially of halide, sulfate, acetate, tosyl, mesyl, benzoate and phosphate;

R¹ is selected from the group consisting essentially of hydrogen, a substituted or unsubstituted C₁-C₁₀ alkyl group and a substituted or unsubstituted C₆-C₁₀ aryl group; and

20

R² is selected from the group consisting essentially of hydrogen, trityl, acetyl, benzyl, benzoyl, dimethoxy trityl, tosyl, mesyl and an acyl radical of an organic carboxylic acid

25



in which R is selected from the group consisting essentially of a substituted or unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₆-C₁₀ aryl group, a substituted or unsubstituted C₄-C₁₀

30

-28-


cycloalkyl group, a substituted or unsubstituted C₇-C₁₂ aralkyl group and a substituted or unsubstituted C₇-C₂₀ cage-type hydrocarbon group.

2. The compound defined in claim 1, wherein Y is chloride.
- 5 3. The compound defined in claim 1, wherein X is bromide.
4. The compound defined in claim 1, wherein X is chloride.
- 10 5. The compound defined in claim 1, wherein X is fluoride.
6. The compound defined in claim 1, wherein X is iodide.
7. The compound defined in claim 2, wherein X is bromide.
- 15 8. The compound defined in claim 2, wherein X is chloride.
9. The compound defined in claim 2, wherein X is fluoride.
- 20 10. The compound defined in claim 2, wherein X is iodide.
11. A process for producing a compound of Formula I:

25

30

-29-



10 wherein:

X is a halide;

Y is selected from the group consisting essentially of halide, sulfate and acetate;

R¹ is selected from the group consisting essentially of hydrogen, a substituted or unsubstituted C₁-C₁₀ alkyl group and a substituted or unsubstituted C₆-C₁₀ aryl group; and

15

R² is selected from the group consisting essentially of hydrogen, trityl, acetyl, benzyl, benzoyl, dimethoxy trityl, tosyl, mesyl and an acyl radical of an organic carboxylic acid

20




25 in which R is selected from the group consisting essentially of a substituted or unsubstituted C₁-C₂₀ alkyl group, a substituted or unsubstituted C₆-C₁₀ aryl group, a substituted or unsubstituted C₄-C₁₀ cycloalkyl group, a substituted or unsubstituted C₇-C₁₂ aralkyl group and a substituted or unsubstituted C₇-C₂₀ cage-type hydrocarbon group, the

30 process comprising the step of reacting a compound of Formula II:

-30-

5



10 with a halogenating compound comprising X.

12. The process defined in claim 11, wherein X is bromide.

13. The process defined in claim 12, wherein the compound of
15 Formula II is initially dissolved in an acidic medium.

14. The process defined in claim 13, wherein the acidic medium is
selected from the group comprising acetic acid, trifluoroacetic acid and
mixtures thereof.

20

15. The process defined in claim 14, wherein the halogenating
compound is bromine.

16. The process defined in claim 15, wherein said bromine is initially
25 dissolved in an organic solvent.

17. The process defined in claim 14, wherein the halogenating
compound is N-bromosuccinimide.

30 18. The process defined in claim 11, wherein X is chlorine.

-31-

19. The process defined in claim 18, wherein the compound of Formula II is initially dissolved in an acidic medium.

20. The process defined in claim 19, wherein the acidic medium is
5 selected from the group comprising acetic acid, trifluoroacetic acid and mixtures thereof.

21. The process defined in claim 14, wherein the halogenating
compound is N-chlorosuccinimide.

10

22. The process defined in claim 11, wherein X is iodide.


23. The process defined in claim 22, wherein the compound of
Formula II is initially dissolved in an acidic medium.

15

24. The process defined in claim 23, wherein the acidic medium is
selected from the group comprising acetic acid, trifluoroacetic acid and
mixtures thereof.

20 25. The process defined in claim 24, wherein the halogenating
compound is N-iodosuccinimide.

1/1



INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 95/00048

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07H19/06 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07H A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,91 13901 (ACIC (CANADA) INC.) 19 September 1991 cited in the application ---	1-25
A	EP,A,0 316 704 (F. HOFFMANN-LA ROCHE AG) 24 May 1989 see the whole document ---	1-25
A	EP,A,0 373 485 (YAMASA SHOYU CO., LTD.) 20 June 1990 see the whole document ---	1-25
A	FR,A,2 199 460 (KABUSHIKI KAISHA KOHJIN) 12 April 1974 see the whole document -----	1-25

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

d document member of the same patent family

Date of the actual completion of the international search

25 April 1995

Date of mailing of the international search report

17.05.95

Name and mailing address of the ISA

European Patent Office, P.O. 5618 Patentamt 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2060, Tr. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Beslier, L

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 95/00048

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9113901	19-09-91	AU-A- 7480191	10-10-91
		EP-A- 0523080	20-01-93
		US-A- 5399682	21-03-95
EP-A-0316704	24-05-89	AU-A- 2516888	25-05-89
		CA-A- 1327358	01-03-94
		CN-B- 1022688	10-11-93
		JP-A- 1153696	15-06-89
		JP-B- 6078350	05-10-94
		SU-A- 1736342	23-05-92
		US-A- 4966891	30-10-90
EP-A-0373485	20-06-90	JP-A- 2256698	17-10-90
		JP-B- 6060194	10-08-94
		US-A- 5026835	25-06-91
FR-A-2199460	12-04-74	NONE	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ ~~FADED TEXT OR DRAWING~~
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ ~~GRAY SCALE DOCUMENTS~~
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)